Diasorin

Diasorin Global leader in the laboratory diagnostics market. Starting from 2021, the company also commercializes Life Science products.

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. The Group was founded in 1968 and is headquartered in Saluggia (Italy). Its line of products used by diagnostic laboratories that are part of hospital facilities or operate independently can meet the needs of the following clini

cal areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology. DiaSorin can offer the market an assay menu that is unique for its width and presence of specialty tests, which identify us as “the” in vitro diagnostics specialist. DiaSorin also provides Life Science products that have a wide range of applications including academic and scientific research, public health and food safety, plant pathogens detection and cell counts, viability, and cell health analyses.

15/06/2026

Payers play a central role in determining which diagnostic tests are adopted and sustained.

In this episode of Beyond the Result, Angelo Rago speaks with Gabriel Bien-Willner, Medical Director of MolDX and Chief Medical Officer at Palmetto GBA, about the intersection of diagnostic stewardship and reimbursement. The discussion spans Z identifier codes, coverage determinations, and the importance of forward-looking policies in molecular diagnostics.

Listen here: https://hubs.li/Q04lrSp-0

12/06/2026

➤ 1 in 200 newborns is diagnosed with congenital CMV every year.
➤ 21 days is the window of time after birth that a newborn should be tested for congenital CMV.
➤ 60 minutes is how quickly Simplexa® Congenital CMV Direct can provide diagnostic results for saliva swab and/or urine samples.

When a newborn may have congenital CMV, timely and accurate detection can make all the difference. To provide the best quality diagnostics for your newborn patients, implement the Simplexa® Congenital CMV Direct assay: the only FDA-cleared PCR assay for the detection of CMV in saliva swabs and urine in neonates.

Discover more about the Simplexa® Congenital CMV Direct assay:
https://hubs.li/Q04lc0SC0

Attending APIC 2026? Visit us at Booth  #1411 to learn more about our molecular diagnostic solutions.We also invite you ...
11/06/2026

Attending APIC 2026? Visit us at Booth #1411 to learn more about our molecular diagnostic solutions.

We also invite you to attend our Exhibitor Theater Session on Tuesday, June 16 at 12:45 PM CST:

Test Faster, Isolate Smarter: Improving Patient Flow While Containing C. auris

Presented by Sarah Elliott, PhD, Scientific Affairs – Diasorin

This session will explore how rapid onsite PCR testing can help healthcare organizations:
• Optimize patient flow and patient cohorting
• Support timely infection prevention decision-making
• Reduce transmission risk across healthcare settings
• Improve operational efficiency and help lower institutional costs
• Strengthen outbreak preparedness and containment strategies

Attendees will also review real-world evidence supporting rapid C. auris screening workflows and learn more about Simplexa® C. auris Direct, the first FDA-authorized assay for detection of C. auris colonization.
https://hubs.li/Q04l63Bw0

Carbapenemase-producing organisms (CPOs) continue to rise, with CDC data showing a 3.8% national increase in 2025. This ...
08/06/2026

Carbapenemase-producing organisms (CPOs) continue to rise, with CDC data showing a 3.8% national increase in 2025. This trend is more than a statistic; it’s an early warning that resistant mechanisms are continuing to spread.

The need for rapid, molecular detection has never been more urgent.

Check out our blog to learn more about these gram-negative threats and how the LIAISON PLEX® Gram-Negative Blood Culture Assay supports broader coverage and faster turnaround for more effective detection and containment.

Read more: https://hubs.li/Q04kq8Xf0

What does it take to make diagnostic stewardship truly actionable in today’s clinical environment?Join us at ASM Microbe...
03/06/2026

What does it take to make diagnostic stewardship truly actionable in today’s clinical environment?

Join us at ASM Microbe 2026 for a live Beyond the Result podcast recording that will include Dr. David Gaston, Medical Director, Molecular Infectious Disease Laboratory at Vanderbilt University Medical Center.

In this session, we’ll explore how innovations in flexible syndromic testing are helping healthcare organizations:
• Deliver more tailored diagnostic strategies
• Enable faster, more informed clinical decisions
• Strengthen diagnostic stewardship across the care continuum

Hear from Dr. Gaston and two other industry leaders in laboratory medicine in support of improving patient outcomes through smarter, more efficient diagnostic testing practices.

Learn more: https://hubs.li/Q04hZ7VR0

We are pleased to be featured in an upcoming ASM Microbe Journal Club session highlighting a recent publication on the 𝐋...
01/06/2026

We are pleased to be featured in an upcoming ASM Microbe Journal Club session highlighting a recent publication on the 𝐋𝐈𝐀𝐈𝐒𝐎𝐍 𝐏𝐋𝐄𝐗® 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐅𝐥𝐞𝐱 𝐀𝐬𝐬𝐚𝐲.

The session will explore age-stratified respiratory pathogen epidemiology and examine the role of customizable syndromic testing in respiratory panel design, drawing from the following publication:

𝐆𝐨𝐧𝐳𝐚𝐥𝐞𝐳 𝐊, 𝐀𝐦𝐢𝐜𝐚𝐫𝐞𝐥𝐥𝐢 𝐆.
Age-Stratified Epidemiology of Respiratory Pathogens and the Value of Customizable Syndromic Testing Using the LIAISON PLEX Respiratory Flex Assay.
https://hubs.li/Q04jBv0g0

Attendees will hear perspectives from academic microbiology leaders representing institutions including Penn Medicine, UC Irvine, the University of Texas Medical Branch, and Johns Hopkins.

Learn more about the Clinical Microbiology Virtual Journal Club on https://hubs.li/Q04jzSGS0: https://hubs.li/Q04jzS9Y0

We look forward to connecting with you at ASM Microbe, Booth #1301.

The rise of carbapenemase-producing organisms (CPOs) remains a serious challenge for healthcare systems. CDC data from 2...
31/05/2026

The rise of carbapenemase-producing organisms (CPOs) remains a serious challenge for healthcare systems. CDC data from 2025 shows a 3.8% national increase, underscoring the urgent need for faster, molecular detection.

Visit our blog to learn more about this growing threat and how molecular panels such as the LIAISON PLEX® Gram-Negative Blood Culture Assay deliver broader coverage and faster turnaround to support containment and stewardship.

Learn more: https://hubs.ly/Q04jvZQv0

Join us at ASM Microbe 2026 for a live Beyond the Result podcast recording featuring Dr. Linoj Samuel, Division Head, Cl...
30/05/2026

Join us at ASM Microbe 2026 for a live Beyond the Result podcast recording featuring Dr. Linoj Samuel, Division Head, Clinical Microbiology, Henry Ford Health System.

This session will explore the practical realities of implementing diagnostic stewardship through flexible syndromic testing, including:
• Integrating diagnostics into everyday clinical workflows
• Bridging the gap between lab data and clinical decision-making
• Supporting antimicrobial stewardship through smarter test utilization

Tune in to hear from Dr. Samuel and esteemed laboratorians for insights into how laboratories and clinicians work together to drive better patient outcomes.

Learn more: https://hubs.li/Q04hXF8j0

Attending ASM Microbe 2026? Tune in for a live Beyond the Result podcast recording that will include Dr. Allison Chambli...
26/05/2026

Attending ASM Microbe 2026? Tune in for a live Beyond the Result podcast recording that will include Dr. Allison Chambliss, Director of Laboratory Stewardship, UCLA, where she and two other esteemed panelists will explore how healthcare systems can move from theory to action.

This session will discuss how flexible syndromic testing can help organizations:
• Move beyond one-size-fits-all diagnostics
• Better match testing to patient presentation
• Improve utilization and stewardship efforts

Step into the future of diagnostic testing at ASM 2026 with Dr. Chambliss and other industry leaders as they share actionable insights you can't afford to miss.

Learn more: https://hubs.li/Q04hYvXv0

How do you reduce respiratory overtesting and cost without losing the confidence of broad panels?In this short video, Ni...
25/05/2026

How do you reduce respiratory overtesting and cost without losing the confidence of broad panels?

In this short video, Nicholas Decker of Holland Hospital shares how his team utilizes the LIAISON PLEX® Respiratory Flex Assay to strengthen stewardship and align testing choices with payor guidelines.

See what Holland Hospital achieved, and what your lab could, too.

Watch the video to learn more: https://hubs.li/Q04fZ0pQ0

Indirizzo

Strada Crescentino Snc
Saluggia
13040

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Diasorin pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Condividi